Guangrong Lu

724 total citations
21 papers, 487 citations indexed

About

Guangrong Lu is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, Guangrong Lu has authored 21 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Guangrong Lu's work include Glioma Diagnosis and Treatment (12 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Guangrong Lu is often cited by papers focused on Glioma Diagnosis and Treatment (12 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Guangrong Lu collaborates with scholars based in United States, China and South Korea. Guangrong Lu's co-authors include Jay‐Jiguang Zhu, Ping Zhu, Xianglin L. Du, Donald M. Foster, Hind Lal, Rakeshwar S. Guleria, David E. Dostal, Suresh K Verma, Metin Akay and Yasemin M. Akay and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Guangrong Lu

19 papers receiving 485 citations

Peers

Guangrong Lu
Joji Ishida Japan
Karina Eterovic United States
Y. Piao United States
Laëtitia Andrique France
Perrine Dahan France
Christopher Duntsch United States
Vashendriya V.V. Hira Netherlands
Kenneth Aldape United States
Jinan Behnan Norway
Julien Dimastromatteo United States
Joji Ishida Japan
Guangrong Lu
Citations per year, relative to Guangrong Lu Guangrong Lu (= 1×) peers Joji Ishida

Countries citing papers authored by Guangrong Lu

Since Specialization
Citations

This map shows the geographic impact of Guangrong Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangrong Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangrong Lu more than expected).

Fields of papers citing papers by Guangrong Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangrong Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangrong Lu. The network helps show where Guangrong Lu may publish in the future.

Co-authorship network of co-authors of Guangrong Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Guangrong Lu. A scholar is included among the top collaborators of Guangrong Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangrong Lu. Guangrong Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Guangrong, et al.. (2024). Development and external validation of a prognostic nomogram to predict survival in patients aged ≥60 years with pancreatic ductal adenocarcinoma. Translational Cancer Research. 13(6). 2751–2766. 1 indexed citations
2.
Huang, Shanshan, Zheng Zhu, Lingxiang Jin, et al.. (2023). Prognostic factors and survival prediction in hepatocellular carcinoma: development and validation of a novel nomogram based on the SEER database. Journal of Gastrointestinal Oncology. 14(4). 1817–1829. 4 indexed citations
3.
Lu, Guangrong, Ping Zhu, Meenakshi B. Bhattacharjee, et al.. (2022). Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. Journal of Neuro-Oncology. 160(1). 221–231. 4 indexed citations
4.
Odia, Yazmín, Ashley Sumrall, Timothy F. Cloughesy, et al.. (2021). Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.. Journal of Clinical Oncology. 39(15_suppl). e14037–e14037. 2 indexed citations
5.
Arrillaga‐Romany, Isabel, Sylvia C. Kurz, Rohinton S. Tarapore, et al.. (2020). Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. Journal of Clinical Oncology. 38(15_suppl). 3615–3615. 1 indexed citations
6.
Lu, Guangrong, et al.. (2020). Full Remission of Long-Term Premenstrual Dysphoric Disorder-Like Symptoms Following Resection of a Pituitary Adenoma: Case Report. American Journal of Case Reports. 21. e922797–e922797.
7.
Gardner, Sharon L., Carl Koschmann, Rohinton S. Tarapore, et al.. (2020). CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS. Neuro-Oncology. 22(Supplement_2). ii45–ii45. 1 indexed citations
8.
Lu, Guangrong, Ping Zhu, Buqing Liang, et al.. (2019). Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. Frontiers in Neurology. 10. 42–42. 52 indexed citations
9.
Hogan, Daniel J., Jay‐Jiguang Zhu, Oscar R. Diago, et al.. (2018). Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients. Clinical Cancer Research. 24(19). 4680–4693. 23 indexed citations
10.
Zorofchian, Soheil, Guangrong Lu, Jay‐Jiguang Zhu, et al.. (2018). Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma. Frontiers in Oncology. 8. 382–382. 30 indexed citations
11.
Akay, Metin, Naze G. Avci, Yantao Fan, et al.. (2018). Drug Screening of Human GBM Spheroids in Brain Cancer Chip. Scientific Reports. 8(1). 15423–15423. 60 indexed citations
12.
Ballester, Leomar Y., Guangrong Lu, Soheil Zorofchian, et al.. (2018). Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathologica Communications. 6(1). 85–85. 49 indexed citations
13.
Zhu, Ping, Xianglin L. Du, Guangrong Lu, & Jay‐Jiguang Zhu. (2017). Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Oncotarget. 8(27). 44015–44031. 70 indexed citations
14.
Valenzuela, Raúl, Meenakshi B. Bhattacharjee, Guangrong Lu, et al.. (2017). NIMG-24. PATHOLOGY CONFIRMED RADIOGRAPHIC DIAGNOSIS OF TRUE PROGRESSION AND PSEUDO-PROGRESSION MADE BY ADVANCED BRAIN TUMOR IMAGING. Neuro-Oncology. 19(suppl_6). vi147–vi147. 1 indexed citations
15.
Yang, Seung Ho, Shenglan Li, Guangrong Lu, et al.. (2016). Metformin treatment reduces temozolomide resistance of glioblastoma cells. Oncotarget. 7(48). 78787–78803. 55 indexed citations
16.
Lu, Guangrong, et al.. (2015). Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma. Molecular Neurobiology. 53(9). 6511–6525. 20 indexed citations
17.
Lu, Guangrong, Travis W. Hein, & Lih Kuo. (2010). Rho Kinase-mediated Coronary Arteriolar Constriction to Endothelin-1: Mechanistic Implications for Cardiac Syndrome X. 1(2). 1 indexed citations
18.
19.
Lal, Hind, Suresh K Verma, Rakeshwar S. Guleria, et al.. (2007). Stretch-induced MAP kinase activation in cardiac myocytes: Differential regulation through β1-integrin and focal adhesion kinase. Journal of Molecular and Cellular Cardiology. 43(2). 137–147. 76 indexed citations
20.
Lal, Hind, Rakeshwar S. Guleria, Donald M. Foster, et al.. (2007). Integrins: Novel Therapeutic Targets for Cardiovascular Diseases. Cardiovascular & Hematological Agents in Medicinal Chemistry. 5(2). 109–132. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joji Ishida Breakdown of academic impact, for papers by Karina Eterovic Breakdown of academic impact, for papers by Y. Piao Breakdown of academic impact, for papers by Laëtitia Andrique Breakdown of academic impact, for papers by Perrine Dahan Breakdown of academic impact, for papers by Christopher Duntsch Breakdown of academic impact, for papers by Vashendriya V.V. Hira Breakdown of academic impact, for papers by Kenneth Aldape Breakdown of academic impact, for papers by Jinan Behnan Breakdown of academic impact, for papers by Julien Dimastromatteo
Rankless by CCL
2026